Non-clinical development of ozanezumab: a humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A) | Zendy

Anthony M. Lynch | Zendy; Matthew Cleveland | Zendy; Rabinder Prinjha | Zendy; Umesh Kumar | Zendy; R. K. Stubbs | Zendy; Jens Wuerthner | Zendy

Open Access

Non-clinical development of ozanezumab: a humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A)

Author(s) -

Anthony M. Lynch,

Matthew Cleveland,

Rabinder Prinjha,

Umesh Kumar,

R. K. Stubbs,

Jens Wuerthner

Publication year - 2015

Publication title -

toxicology research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.709

H-Index - 31

eISSN - 2045-4538

pISSN - 2045-452X

DOI - 10.1039/c5tx00179j

Subject(s) - neurite , amyotrophic lateral sclerosis , monoclonal antibody , antibody , cancer research , medicine , microbiology and biotechnology , chemistry , immunology , biology , biochemistry , in vitro , pathology , disease

Ozanezumab (GSK1223249) is a humanised, Fc-disabled, monoclonal antibody (mAb) which targets the amino terminus of Neurite Outgrowth Inhibitor A (Nogo-A) which is currently being developed for the treatment of amyotrophic lateral sclerosis (ALS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research